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ABSTRACT 
Segmental multi-frequency bioelectrical impedance analysis (SMF-BIA) has 
been shown to be a valid, more portable, and less expensive alternative to dual energy 
x-ray absorptiometry (DXA) for the measurement of appendicular lean mass (ALM) in 
several populations.  However, few studies have examined the validity of SMF-BIA 
specifically among populations of older women classified as sarcopenic or dynapenic.  
The aim of this cross sectional study was to investigate the accuracy of SMF-BIA 
compared to the gold standard DXA for the measurement of ALM among sarcopenic 
and/or dynapenic older women.  Physical function, ALM, strength, and 
anthropometric tests were performed to determine the presence of sarcopenia and/or 
dynapenia in a sample of 25 older (72.3 ± 4.6 years) women using established 
sarcopenia classification criteria.  Estimation of ALM using SMF-BIA and DXA were 
performed under standardized testing conditions.  Both techniques were administered 
within the same hour with participants adequately hydrated, fasted, following urine 
elimination, and while wearing hospital scrubs.  A Pearson correlation coefficient was 
used to determine a relationship between the two methods for ALM and agreement 
between the two techniques was assessed using a Bland-Altman plot method.  
Statistical significance was set at p < 0.05.  A significant and strong correlation was 
observed between the two techniques with a Pearson’s correlation coefficient of 0.88 
(95% CI= 0.75 to 0.95; p < 0.001).  The Bland-Altman plot showed a mean difference 
of 0.5 kg and an indication of overall agreement between techniques.  However, SMF-
BIA overestimated ALM for one participant (-2.9 kg, 95% CI= -3.76 to -2.03) and 
underestimated ALM for another participant (1.8 kg, 95% CI= 0.98 to 2.71) compared 
 
 
to DXA.  The findings indicate overall agreement between SMF-BIA and DXA for the 
estimation of ALM among older women with characteristics of sarcopenia, but SMF-
BIA may overestimate or underestimate ALM in some individuals.  These data 
suggest that SMF-BIA may be an acceptable alternative to DXA for the assessment of 
ALM in older women with characteristics of sarcopenia.   
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PREFACE 
This thesis is written to comply with the University of Rhode Island graduate 
school manuscript format.  The thesis document contains one manuscript: Validation 
of Bioelectrical Impedance Analysis for the Measurement of Appendicular Lean Mass 
in Older Women.  The manuscript has been written in a form formatted for publication 
in the International Journal of Body Composition Research. 
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ABSTRACT 
 
Objective: Segmental multi-frequency bioelectrical impedance analysis (SMF-BIA) 
has been shown to be a valid, more portable, and less expensive alternative to dual 
energy x-ray absorptiometry (DXA) for the measurement of appendicular lean mass 
(ALM) in several populations.  However, few studies have examined the validity of 
SMF-BIA specifically among populations of older women classified as sarcopenic or 
dynapenic.  The aim of this cross sectional study was to investigate the accuracy of 
SMF-BIA compared to the gold standard DXA for the measurement of ALM among 
sarcopenic and/or dynapenic older women.   
Methods: Physical function, ALM, strength, and anthropometric tests were performed 
to determine the presence of sarcopenia and/or dynapenia in a sample of 25 older (72.3 
± 4.6 years) women using established sarcopenia classification criteria.  Estimation of 
ALM using SMF-BIA and DXA were performed under standardized testing 
conditions.  Both techniques were administered within the same hour with participants 
adequately hydrated, fasted, following urine elimination, and while wearing hospital 
scrubs.  A Pearson correlation coefficient was used to determine a relationship 
between the two methods for ALM and agreement between the two techniques was 
assessed using a Bland-Altman plot method.  Statistical significance was set at p < 
0.05.   
Results: A significant and strong correlation was observed between the two 
techniques with a Pearson’s correlation coefficient of 0.88 (95% CI= 0.75 to 0.95; p < 
0.001).  The Bland-Altman plot showed a mean difference of 0.5 kg and an indication 
of overall agreement between techniques.  However, SMF-BIA overestimated ALM 
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for one participant (-2.9 kg, 95% CI= -3.76 to -2.03) and underestimated ALM for 
another participant (1.8 kg, 95% CI= 0.98 to 2.71) compared to DXA.   
Discussion: The findings indicate overall agreement between SMF-BIA and DXA for 
the estimation of ALM among older women with characteristics of sarcopenia, but 
SMF-BIA may overestimate or underestimate ALM in some individuals.  These data 
suggest that SMF-BIA may be an acceptable alternative to DXA for the assessment of 
ALM in older women with characteristics of sarcopenia.   
Keywords: Sarcopenia, DXA 
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INTRODUCTION 
Sarcopenia is defined as the progressive loss of muscle mass, physical 
function, and strength (i.e. dynapenia) which accelerates with aging [1–3].  Sarcopenia 
is associated with several adverse health outcomes among older adults including 
frailty, weakness, functional decline, increased risk of falls and fractures, and loss of 
independence [1,2].  In the year 2000, estimated healthcare costs associated with 
sarcopenia were $12.6 billion for older men, and $29.5 billion for older women [4].  
The economic burden associated with sarcopenia is likely far higher today particularly 
in women, as they have a greater life expectancy and risk for functional impairment 
compared to men [5].  Although a universally accepted definition for sarcopenia is 
currently lacking, several working groups have convened to establish operational 
criteria for classification including measures of physical function, strength, and muscle 
mass. 
While a wide range of techniques are available for assessing muscle mass, dual 
energy X-ray absorptiometry (DXA) is considered as the gold standard in research and 
clinical practice to determine appendicular lean mass (ALM) despite its limitations 
including exposure to radiation, expense, and lack of portability [2,6–8].  Thus, is it 
critical to find alternative methods for ALM assessment.   
The use of segmental multi-frequency bioelectrical impedance analysis (SMF-
BIA) for the measurement of muscle mass has been accepted as a valid, more portable, 
and less expensive alternative in several populations [9–12] including older women 
[13,14]. While one study has validated the use of SMF-BIA for the estimation of ALM 
among a general population of older women [13], the device has not yet been 
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validated for the assessment of ALM and its application to sarcopenia identification 
based on several accepted definitions.  Thus, the purpose of this investigation was to 
assess whether SMF-BIA would accurately quantify ALM compared to DXA among a 
population of older women with characteristics of sarcopenia and/or dynapenia.  It was 
hypothesized that SMF-BIA would be in agreement with DXA for the estimation of 
ALM.  A secondary aim was to examine if SMF-BIA similarly classifies older women 
as sarcopenic compared to DXA based on ALM compared to height or body mass 
index (BMI) using established cut-points. 
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METHODS 
Study Design 
The study utilized a cross-sectional design to compare differences between 
SMF-BIA and DXA for the estimation of ALM among 25 older women pre-screened 
for the presence of sarcopenia and/or dynapenia (reduced strength).  The participants 
were pre-screened for entry into a 12-week University of Rhode Island Institutional 
Review Board approved, Resistance Exercise Study to Reclaim Lean Muscle and 
Strength (URI RESTORE ME Project: IRB # HU1415-168).  The two techniques 
being compared for this study were performed at baseline of the URI RESTORE ME 
project. 
Participants   
Community dwelling women (n = 25) aged 65 to 84 years were recruited from 
Rhode Island via flyers, newspaper ads, press releases, and by word of mouth within 
local senior centers.  All women initially eligible based on information provided 
during a telephone screening were invited to an onsite orientation and pre-screening 
assessment.  During pre-screening, all women provided written informed consent and 
were evaluated for the presence of sarcopenia and/or dynapenia determined from the 
assessment of lean mass, height, weight, grip strength, single chair stand, and gait 
speed based on the European Working Group on Sarcopenia in Older People 
(EWGSOP) and the Foundation for the National Institute of Health Sarcopenia Project 
(FNIHSP) criteria.  The pre-screening visit determined that 38 participants were 
eligible based on the sarcopenia criteria.  Although eligible, 13 participants were 
7 
 
subsequently eliminated from the final cohort due to questions of time commitment or 
orthopedic concerns that would limit full participation in the intervention phase of the 
project.  Figure 1 summarizes each phase of study recruitment.  
Outcome Measures 
All testing sessions were standardized with participants arriving in the morning 
in a fasted state.  Participants were instructed to arrive well hydrated and having not 
exercised.  Both techniques for measuring body composition were performed on the 
same day, within the same hour, and following urine elimination.  All participants 
were dressed in hospital scrubs for both methods.   
Appendicular Lean Mass: ALM was estimated using fan-beam technology (GE 
Lunar iDXA, Waukesha, WI).  The DXA scans were performed using a standardized 
procedure for patient positioning by a licensed radiology technician.  The DXA scans 
provided estimations of ALM defined as the total skeletal muscle mass from the right 
arm, left arm, right leg, and left leg measured in kilograms.  
In addition to DXA, a SMF-BIA was used to estimate segmental muscle mass 
whereby ALM could then be calculated.  The InBody 570 Biospace device (Biospace 
Co, Ltd, Korea) was used according to the manufacturer’s guidelines during both the 
pre-screening assessment (to determine sarcopenia status) and baseline testing to 
assess ALM.  Body composition is estimated via SMF-BIA using the difference of 
conductivity of various tissues due to the differences in their biological characteristics.  
The risk of adverse events is low using SMF-BIA and its use has been performed 
safely on older adults in other studies [15].  As a precaution, women with a cardiac 
pacemaker or internal defibrillator were not tested.   
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Sarcopenia Status:  Prior to the collection of baseline testing data, participants 
completed pre-screening to determine their eligibility as presenting with sarcopenia 
and/or dynapenia.  An algorithm for determining eligibility was developed based on a 
combination of both the EWGSOP and FNIHSP working definitions for sarcopenia.  
Initial ALM estimates using SMF-BIA in addition to outcomes of physical function 
using the gait speed, single chair stand, and grip strength tests were included in the 
algorithm.  The cut-points established for each criteria included an ALM < 5.67 kg/m2 
or ALM/BMI < 0.512, a grip strength < 20 kg or inability to complete a single chair 
stand, and a gait speed < 0.8 m/s [2,16].  Women selected were classified as having 
low lean mass (LM), low strength, low function (slow gait), or all three characteristics.        
Physical Function:  As part of the short physical performance battery (SPPB) 
of tests, usual gait speed was measured during pre-screening and during baseline to 
assess physical function and as a fundamental criterion for defining sarcopenia status.  
Gait speed has been suggested as being included in routine evaluations as the sixth 
vital sign [7] as it is a strong predictor of major health outcomes and survival in older 
adults [6].  The EWGSOP, International Working Group (IWG), and FNIHSP are all 
in agreement that a gait speed < 0.8 m/s should be used as a cut-point for identifying 
sarcopenia in older adults [2,16,18].  Standardized protocols were utilized for 
administration of the gait speed test which required participants to walk 4 meters at a 
usual pace [19].  The test was repeated twice with the faster of the two trials recorded 
in seconds.         
Muscle Strength: Grip strength is reliable, valid, and simple to administer in 
both clinical and community settings and is a predictor of mobility impairment 
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[20,21].  Grip strength was tested during pre-screening and during baseline using a 
handgrip dynamometer (Jaymar Hydraulic Dynamometer, J.A. Preston, Corp., 
Jackson, MS).  The test was performed with the participant seated in a chair with the 
elbow bent to 90 degrees using a standardized protocol [22].  The dynamometer was 
set accordingly based on each individual’s hand size so that the second knuckle of all 
four fingers rested flat on the handle.  Two trials were performed on each hand and the 
highest score was recorded in kilograms without accounting for hand dominance.  
Grip strength values < 20 kg were also used as criteria for determining the presence of 
sarcopenia and/or dynapenia.  Participants also completed a single chair stand test to 
assess lower body strength using a standardized protocol [23].  The test required that 
the participant rise from a chair with the arms crossed over the chest and with both 
feet flat on the floor.  The ability or inability to rise from the chair was recorded and 
used to classify individuals as weak (i.e. dynapenia). 
Anthropometrics: Each participant’s height and weight were measured twice 
and the average of the two readings were used.  Height and weight were measured 
with each participant barefoot and wearing hospital scrubs.  Height was measured 
using a wall mounted stadiometer and weight was recorded using the InBody 570 
SMF-BIA device.  From these measurements, BMI was calculated by dividing the 
participants weight in kilograms by their height in meters squared. 
Other Measures 
Physical Activity: To assess each participant’s physical activity level, the Yale 
Physical Activity Survey (YPAS) was administered during baseline testing.  The 
YPAS quantifies the type and intensity of physical activity among older adults 
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estimating total energy expenditure (kcals/week) and a total activity summary index.  
The YPAS has been shown to be a valid measurement for the assessment of physical 
activity among older adults [24].  The YPAS was used to describe physical activity 
patterns of the participant population.   
Dietary Intake: Participants completed a Dietary Screening Tool (DST) 
developed for older adults at baseline to assess dietary patterns [25].  The DST 
identifies 3 levels of nutritional risk: at risk (< 60), at possible risk (60 to 75), and not 
at risk (> 75) [26].  Nutritional risk assessed with the DST was used to describe the 
participant population. 
Statistical Analysis 
Estimated between-group differences were calculated for the primary 
outcomes, and a paired t-test was used to compare differences in estimated ALM by 
SMF-BIA and DXA.  A previous study comparing SMF-BIA and DXA among frail 
women 75 years or older demonstrated an overall mean difference for ALM between 
the two techniques as 0.08 ± 0.05 kg [13].  Based on the findings of this study, a 
sample size of 16 were required to provide sufficient power (0.80) and alpha at 0.05.   
Clinical and demographic characteristics of the participants are expressed as 
mean ± standard deviation.  A Shapiro-Wilk test was performed to verify that data for 
the primary outcome variables were within normal distribution.  To determine the 
strength of the relationship between the two variables, a Pearson moment correlation 
coefficient was performed.  To test the primary hypothesis, a Bland-Altman method 
was employed to compare agreement between DXA and SMF-BIA whereby the 
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differences in techniques are plotted against the averages of the two techniques [27].  
To test the secondary hypothesis, a Fisher’s exact test was used to compare sarcopenia 
status based on ALM between the two techniques.  Statistical analyses were performed 
using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA). 
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RESULTS 
 A total of 25 female participants with a mean age of 72.3 ± 4.6 years were 
enrolled in this study.  Demographic characteristics, anthropometric measures, 
indictors of physical functioning, physical activity, and dietary habits of the study 
population are summarized in Table 1.   
A significant difference (p = 0.0145) was observed between DXA and SMF-
BIA for the measurement of ALM by a mean of 0.5 kg for each participant.  
Additionally, a 4.3% error of ALM by SMF-BIA was observed compared to DXA as 
the gold standard (p = 0.0162).  A significant and strong positive correlation was 
observed between SMF-BIA and DXA as indicated by a Pearson’s correlation 
coefficient of 0.88 (95% CI= 0.75 to 0.95, p < 0.001) highlighted in Figure 2.  In 
addition, agreement between the two methods was assessed using a Bland-Altman plot 
(Figure 3).  A mean difference of 0.5 kg (95% CI= -1.02 to -0.02) indicates overall 
agreement between SMF-BIA and DXA.  However, SMF-BIA overestimated ALM 
for one participant (-2.9 kg, 95% CI= -3.76 to -2.03) and underestimated ALM for 
another participant (1.8 kg, 95% CI= 0.98 to 2.71) compared to DXA. 
When comparing sarcopenia status based on ALM measured by SMF-BIA and 
DXA, the Fisher’s exact test indicates a significant difference (p < 0.001) between the 
two techniques when using both the EWGSOP and FNIHSP criteria.  Of the 25 
women found to demonstrate characteristics of sarcopenia and/or dynapenia based on 
EWGSOP criteria during pre-screening, SMF-BIA identified less participants (n = 7) 
as sarcopenic compared to DXA (n = 11).  While SMF-BIA and DXA similarly 
identified the normal and pre-sarcopenic participants, DXA was able to identify more 
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participants as having sarcopenia based on current EWGSOP criteria (Table 2).  
Similarly, DXA was able to identify more participants as having low lean mass (n = 9) 
compared to SMF-BIA (n = 6) based on FNIHSP criteria (Table 3).   
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DISCUSSION 
 The results of this study indicate overall agreement between SMF-BIA and 
DXA for the estimation of ALM among older women with characteristics of 
sarcopenia and/or dynapenia.  A significant and strong correlation (r = 0.88) and the 
lack of significant difference between the two techniques indicates acceptability of 
SMF-BIA compared to DXA.  The Bland Altman plot provided a visual judgement of 
agreement between techniques with a mean overestimation of ALM by SMF-BIA of 
0.5 kg.  While most participants fell within the 95% limits of agreement, two outliers 
were identified.  The plot indicates that SMF-BIA overestimated ALM but was not 
statistically different from DXA.  The results of the present study are in line with 
previous studies which support that SMF-BIA is a valid, more portable, and affordable 
alternative to DXA for the estimation of ALM [7,9,10,13,14].  
While the study indicates that SMF-BIA is a valid alternative to DXA, DXA 
appears to be more reliable for assessing ALM for diagnosing sarcopenia.  Criteria for 
sarcopenia classification required that the participants ALM be < 5.67 kg/m2 or 
ALM/BMI < 0.512 in combination with weak grip strength (< 20 kg) and/or slow gait 
speed (< 0.8 m/s).  These findings suggest that SMF-BIA may overestimate ALM just 
enough to allow some participants to be above the sarcopenia ALM cut-off value.  
While the grip strength and gait speed functional outcomes stand alone to identify 
individuals at risk for sarcopenia, DXA is the most reliable method for identifying 
sarcopenic females based on ALM.  Although overall agreement between SMF-BIA 
and DXA for the estimation of ALM was observed in this study, investigators should 
use caution when using some impedance models for diagnosing sarcopenia.      
15 
 
 In agreement with these findings, previous studies have demonstrated that 
SMF-BIA is a valid alternative to DXA for the estimation of ALM among healthy 
adult [9,10] and older female participants [13,14].  Andersen et al. [10] determined 
that similar SMF-BIA devices, namely the InBody 520 and 720, were valid for the 
estimation of ALM among healthy young women between the ages of 18 and 49 years.  
While both devices were strongly correlated to DXA, (r = 0.62 - 0.87) the conclusions 
were that SMF-BIA underestimated ALM by approximately 1.0 kg in the 25 female 
participants.  Similar results were observed by Leahy et al. [9] with BIA 
underestimating arm and leg fat free mass by 0.2 kg (2.4 %) and 0.8 kg (3.4 %), 
respectively, in men and 0.2 kg (4.5 %) and 0.7 kg (4.4 %), respectively, in women (p 
< 0.001).  Another similar study identified SMF-BIA as an appropriate alternative to 
DXA for the estimation of fat mass, percent body fat, and total lean mass, but not for 
the evaluation of ALM among a healthy adult population between 18 and 85 years 
[12].  Although the present study identifies the InBody 570 SMF-BIA device to be a 
valid alternative to DXA, the tendency for SMF-BIA to overestimate or underestimate 
ALM in some participants did occur as consistent with previous study findings.  
Conflicting results regarding the agreement between SMF-BIA and DXA 
specifically for the measurement of ALM among elderly women have also been 
reported in other similar studies [7,13,14].  Buckinx et al. [7] observed low agreement 
between the two methods among approximately 25 women in the subcategory of 
participants over the age of 65 (n = 48) using a Bland-Altman plot method.  The study 
reported a tendency for SMF-BIA to overestimate ALM by approximately 1.75 kg [7].  
Other studies investigating older women report acceptable accuracy of SMF-BIA 
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compared to DXA for the estimation of ALM.  Among an older female Japanese 
population (n = 330) aged 65 to 87 years old, SMF-BIA tended to underestimate ALM 
by 1.59 kg (95% CI= 1.49 to 1.68) [14].  Segmental multi-frequency BIA also 
provided acceptable accuracy for the estimation of ALM among frail women 75 years 
and older with a tendency to underestimate ALM (r = -1.42, p < 0.01) [13].  In the 
present study, despite significant differences in sarcopenia definitions between SMF-
BIA and DXA, the Bland-Altman plot indicated overall agreement between the two 
methods for the estimation of ALM with a mean difference of 0.5 kg among the older 
female participants. 
This study has both strengths and weaknesses.  The main strength was the use 
of standardized testing conditions.  All participants were instructed to arrive for testing 
fasted, well hydrated, having not exercised, and following urine elimination.  These 
confounding variables were well-controlled in addition to SMF-BIA and DXA being 
performed within the same hour.  Hydration status upon arrival for testing was 
assessed based on self-report in addition to a normal ratio of extracellular water to 
total body water content (ECW/TBW) estimated by SMF-BIA.  All participants 
ECW/TBW ratios were within the normal range of 0.36 to 0.39 as defined by the 
InBody manufacturer.  The use of DXA as the gold standard method for body 
composition analysis by which SMF-BIA could be compared was an additional 
strength of the present study.   
Potential limitations include the small sample size and homogeneity of the 
participant population as the results may not be generalizable to other populations.  A 
larger sample size of older women including those from different racial, ethnic, and 
17 
 
socioeconomic backgrounds could have demonstrated more similarity between SMF-
BIA and DXA using Fisher’s exact analysis.  The present study was limited to 
investigating the validity of only one of many SMF-BIA devices, the InBody 570.  
Additionally, the study was cross sectional therefore, future studies should examine 
changes in ALM longitudinally and following interventions.   
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CONCLUSION 
While previous studies have investigated the validity of SMF-BIA for 
estimation of ALM compared to DXA among older women, this is the first study to 
validate SMF-BIA in a population of older women who present with sarcopenia and/ 
or dynapenia.  In conclusion, the present study confirmed overall agreement between 
SMF-BIA and DXA for the measurement of ALM among older women who present 
with characteristics of sarcopenia and/or dynapenia based on current definitions.  It is 
possible however, that SMF-BIA may overestimate or underestimate ALM in some 
participants.  While SMF-BIA is an acceptable, less expensive, and more portable 
alternative to DXA for measuring ALM, future studies are required using other 
devices and larger samples to justify that SMF-BIA is more realistic for clinical and 
epidemiological identification of sarcopenia based on current definitions.   
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TABLES 
Table 1. Baseline Participant Characteristics 
 Mean (SD) Minimum Maximum 
Age  72.3 (4.6) 66 81 
Weight (kg) 65.3 (13.5) 47 100.7 
Height (cm) 159.8 (5.2) 149.9 168.9 
BMI (kg/m2) 25.7 (5.8) 18.9 42 
% Body Fat 42.5 (6.3) 28.1 55.8 
Gait Speed 
(meters/second) 
0.97 (0.12) 0.68 1.18 
Grip Strength (kg) 16.6 (3.7) 10 28 
Physical Activity 
(kcals/week) 
6,912 (3,270) 1,183 13,350 
Physical Activity 
Index 
49.6 (22.1) 16 103 
Dietary Patterns  73.3 (6.4) 52 82 
*Abbreviation: BMI, Body Mass Index 
*Physical Activity and dietary patterns derived from the Yale Physical Activity Survey 
*Dietary Patterns derived from the Dietary Screening Tool 
< 60 = at risk, 60-75 = at possible risk, >75 = not at risk (Bailey et al., 2009)26 
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Table 2. Fisher’s Exact Test for Sarcopenia Classification Based on European 
Working Group on Sarcopenia in Older People (EWGSOP) Definition Comparing 
Segmental Multi-frequency Bioelectrical Impedance (SMF-BIA) and Dual Energy X-
ray Absportiometry (DXA) 
 DXA 
Normal 
DXA Pre-
Sarcopenia 
DXA 
Sarcopenia 
DXA 
Weak 
Total 
SMF-BIA 
Normal 
3 0 0 0 3 
SMF-BIA Pre-
Sarcopenia 
0 1 0 0 1 
SMF-BIA 
Sarcopenia 
0 0 7 0 7 
SMF-BIA 
Weak 
0 0 4 10 14 
Total 3 1 11 10 25 
*Normal = ALM > 5.67 kg/m2, Grip Strength > 20 kg, and Gait Speed > 0.8 m/s 
*Pre-Sarcopenia = ALM <5.67 kg/m2, Grip strength > 20 kg, and Gait Speed > 0.8m/s 
*Sarcopenia = ALM <5.67 kg/m2 and Grip < 20 kg or Gait Speed < 0.8 m/s 
*Weak = ALM > 5.67 kg/m2 and Grip < 20 kg 
NOTE:  Significant difference between definitions (p < 0.001) 
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Table 3. Fisher’s Exact Test for Sarcopenia Classification Based on the Foundation 
for the National Institute of Health Sarcopenia Project (FNIHSP) Definition 
Comparing Segmental Multi-frequency Bioelectrical Impedance (SMF-BIA) and Dual 
Energy X-ray Absportiometry (DXA) 
 DXA 
Low 
Lean 
DXA 
Normal 
DXA 
Weak 
Total 
SMF-BIA Low 
Lean  
6 0 0 6 
SMF-BIA 
Normal 
3 7 0 10 
SMF-BIA 
Weak 
0 0 9 9 
Total 9 7 9 25 
*Normal = ALM > 15.02 kg or ALM/BMI > 0.512 and Grip Strength > 16 kg 
*Low Lean = ALM < 15.02 kg or ALM/BMI < 0.512 and Grip > 16 kg 
*Weak = ALM > 15.02 kg or ALM/BMI > 0.512 and Grip <16 kg 
NOTE:  Significant difference between definitions (p < 0.001) 
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FIGURES 
 
 
Figure 1. Study Flow Chart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phone Screened for 
Initial Eligibility 
(n=160)
Excluded (n=99)
-Did not meet eligibility 
criteria (n=70)
-Unavailable for time 
commitment (n=9)
-Not interested (n=20)
Pre-Screened for Eligiblity (n=61)
-Provided Informed Consent
-Assessment of body composititon, 
grip strength, single chair stand, and 
gait speed
Excluded (n= 23)
-Did not meet sarcopenia or 
dyanapenia guidelines
Eligible (n=38)
-Investigator Review 
for selection
Baseline Tested 
(n=25)
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Figure 2. Pearson’s Correlation Coefficient Between Segmental Multi-frequency 
Bioelectrical Impedance (SMF-BIA) and Dual Energy X-ray Absorptiometry (DXA) 
for the Measurement of Appendicular Lean Mass (ALM) 
 
 
*A significant and strong positive correlation was observed between SMF-BIA and DXA with a 
correlation coefficient of 0.88 (95% CI= 0.75 to 0.95, p < 0.001). 
 
 
 
 
r = 0.88 
p < 0.001 
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Figure 3. Bland-Altman Plot Comparing Appendicular Lean Mass (ALM) by 
Segmental Multi-frequency Bioelectrical Impedance (SMF-BIA) and Dual Energy X-
ray Absorptiometry (DXA) 
 
*A mean difference of 0.5 kg (95% CI= -1.02 to -0.02) indicates overall agreement between 
SMF-BIA and DXA. 
*SMF-BIA overestimated ALM for one participant (-2.9 kg, 95% CI= -3.76 to -2.03) and 
underestimated ALM for another participant (1.8 kg, 95% CI= 0.98 to 2.71) compared to 
DXA. 
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APPENDICES 
Appendix A: Review of the Literature 
 
Abstract 
 The loss of muscle mass associated with advancing age, termed sarcopenia, 
contributes to the development of physical disability and mobility limitation.  Women 
are at a greater risk for developing physical disability compared to men as patterns of 
functional impairment related to the loss of muscle and strength (i.e. dynapenia) differ 
between genders.  Although a universally accepted definition for sarcopenia is lacking, 
several working groups have established criteria based on low appendicular lean mass 
(ALM) and poor physical function.  While dual energy x-ray absorptiometry (DXA) is 
considered as the gold standard method for measuring ALM, several studies have 
validated the use of segmental multi-frequency bioelectrical impedance (SMF-BIA) as 
a more portable alternative.  No study to date has assessed the accuracy of SMF-BIA 
among older women who present with characteristics of sarcopenia and/or dynapenia. 
 
Introduction  
Sarcopenia is defined as the progressive loss of muscle mass, physical 
function, and strength (i.e. dynapenia) which accelerates with advancing age.1–3  The 
mechanisms for sarcopenia are multifactorial and include physical inactivity, 
malnutrition, hormonal changes, denervation of motor units, and the conversion of fast 
type II muscle fibers to slow type I muscle fibers, among others.2,4  As a natural 
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process of aging, muscle mass declines by approximately 1 to 2% per year after age 50 
contributing to the loss of strength at an even greater rate.1,5,6  Muscle strength has 
been reported to decline 2 to 5 times faster than muscle mass with age contributing to 
poor physical function, mobility limitation, and disbaility.7–9  Sarcopenia is associated 
with several adverse health outcomes among older adults including frailty, weakness, 
functional decline, increased risk of falls and fractures, and loss of independence.1,2  
Moreover, in the year 2000, estimated healthcare costs associated with sarcopenia 
were $12.6 billion for older men, and $29.5 billion for older women.10  The economic 
burden associated with sarcopenia is likely far higher today particularly in women, as 
they have a greater life expectancy and risk for functional impairment compared to 
men.11,12   
Although there is currently no universal definintion for identifying sarcopenic 
individuals, several working groups have established cut-points for low lean mass in 
addition to markers of reduced physical functioning and muscle strength.  While early 
definitions were based exclusively on muscle mass compared to a healthy reference 
population,13 the current definitions also consider performance criteria.  The European 
Working Group on Sarcopenia in Older People (EWGSOP), the Foundation for the 
National Intistutes of Health Sarcopenia Project (FNIHSP), and the International 
Working Group (IWG) are all in agreement that ALM in combination with weak grip 
strength and or slow gait speed be present to confirm sarcopenia status.     
While a wide range of techniques are available for assessing muscle mass, 
DXA is considered as the gold standard in research and clinical practice to determine 
ALM despite its limitations including exposure to radiation, expense, and lack of 
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portability.2,14,15,4  Thus, is it critical to find alternative methods for ALM assessment.  
The use of segmental multi-frequency bioelectrical impedance analysis (SMF-BIA) 
for the measurement of muscle mass has been accepted as a valid, more portable, and 
less expensive alternative in several populations16–19 including older women.20,21  
While some studies have validated the use of SMF-BIA for the estimation of ALM 
among older women,20 the device has not yet been validated for the assessment of 
sarcopenia based on current international definitions. 
 
Sarcopenia in Older Women 
Women represent the largest proportion of the elderly, and their patterns of 
functional impairment related to declines in muscle mass and strength differ from 
men.12  Women are at a greater risk for developing decreased muscle strength 
(dynapenia) and sarcopenia with aging which also increases their risk for mortality 
compared to men as they have more fat, lower absolute muscle mass, and less 
strength.1,22  The earlier development of muscle weakness observed in women 
compared to men can be partially explained by menopause as a reduction in the sex-
hormone estrogen is associated with loss of bone mass and strength.11,23  Changes in 
the sex hormones estrogen and progesterone begin a decade or more prior to 
menopause, which may accelerate the morphological changes in skeletal muscle 
characteristic of sarcopenia.  Consequently, post-menopausal women present with half 
the concentration of estrogen observed before menopause thus increasing their 
incidence of sarcopenia.24   
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Women also experience earlier declines in muscle power at a rate of 3 to 4% 
faster than strength compared to men.24  Early declines in muscle power, defined as 
the ability to perform muscular work per unit of time could explain the variance in 
poorer physical function and subsequent disability.24,25  A longitudinal study followed 
545 high-functioning women aged 75 years and older over a seven-year period to 
determine which baseline activities of daily living were most strongly predictive of 
future disability.  Women with poor mobility measured by time to complete five chair 
stands, gait speed, and number of steps to walk 6 meters had odds ratios (95% CI) 
equal to 7.62 (3.86, 15.04), 6.31 (3.26, 12.19) and 5.31 (2.43, 11.59), respectively, for 
developing disability while women with poor grip strength had 2.81 (1.43, 5.52) times 
the risk of developing disability.12  Given that women experience a greater life 
expectancy as well as greater functional impairment associated with muscle weakness, 
early identification of muscle loss using accurate and clinically available techniques is 
especially important so that appropriate interventions can be delivered to reduce 
adverse health outcomes and improve quality of life.11 
 
Working Definitions for Sarcopenia 
 Screening individuals for clinically significant sarcopenia has presented as a 
major challenge for the justification of intervention strategies that could reduce 
disability among older adults without a universally accepted definition.  As a result, 
several working groups have convened to establish criteria to identify individuals at 
risk in order to prevent adverse events associated with reduced lean mass (LM) and 
physical function.13,26  Muscle mass can be quantified using DXA, SMF-BIA, and 
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anthropometry while muscle strength can be measured most effectively by testing 
handgrip strength using a handheld dynamometer.27  In clinical practice, physical 
performance is measured using the short physical performance battery (SPPB) of tests, 
the get up and go test, and gait speed.  The most prominent statements defining 
sarcopenia based on low muscle mass and physical function have come from the 
European Working Group on Sarcopenia in Older People (EWGSOP), International 
Working Group (IWG), and the Foundation for the National Institutes of Health 
Sarcopenia Project (FNIHSP).  While early definitions were based exclusively on 
muscle mass compared to a healthy reference population, the current definitions also 
consider performance criteria.13   
The EWGSOP algorithm requires that low muscle mass accompanied by either 
low grip strength, slow gait speed, or a combination of all three be present for 
classification of pre-sarcopenia, sarcopenia, or severe sarcopenia.2,13  The EWGSOP 
defines low muscle mass as an ALM in kilograms relative to height squared (kg/m2) 
less than 7.23 kg/m2 in men and less than 5.67 kg/m2 in women.  Their cutoff values 
for low grip strength are set at less than 30 kg in men and less than 20 kg in women.  
In order to be considered slow, and individual must present with a gait speed less than 
0.8 meters per second (m/s).  Based on the results from screening of the above 
mentioned criteria, the severity of sarcopenia may be determined.  Pre-Sarcopenia is 
defined by low muscle mass without low muscle strength whereas severe sarcopenia is 
defined by demonstrating all three criteria.  Individuals with sarcopenia present with 
low muscle mass in combination with either low grip strength or slow gait speed.    
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 The International Working Group defines sarcopenia as the age related loss of 
skeletal muscle mass and function caused by several factors including disuse, altered 
endocrine function, chronic diseases, inflammation, insulin resistance, and nutritional 
deficiencies which contribute to disability, hospitalization, and death.28  The group 
considers that all older patients who present with observed decrements in physical 
function, strength, and overall health be evaluated.  Their diagnosis of sarcopenia is 
based on the presence of low whole body or ALM in combination with poor physical 
functioning.  Similar to the EWGSOP criteria, the IWG confirms diagnosis of 
sarcopenia based on the same ALM criteria however, their cut-points are less 
conservative with slow gait speed defined as less than 1.0 m/s.28 
Rather than define sarcopenia, the FNIH have proposed a two-step clinical 
paradigm to identify individuals with low muscle strength and low muscle mass by 
first screening for mobility impairment and low muscle strength measured by gait 
speed and grip strength, respectively.13,29  The FNIHSP recommends that individuals 
be identified using either “weak with low LM” or “weak and slow with low LM” 
rather than use the term sarcopenia.30  The group is in agreement with the EWGSOP 
and IWG on the use of a cut-point for slow gait speed defined as less than 0.8 m/s, as 
it is easy to measure in most settings and is highly predictive of survival and major 
health outcomes.31  The cut-points established to identify weak individuals based on a 
grip strength are set as less than 26 kg in men and less than 16 kg in women compared 
to the EWGSOP criteria (< 30 kg in men and < 20 kg in women).32  Their criteria for 
low LM is defined as an ALM < 19.75 kg for men and < 15.02 kg for women and the 
criteria for low LM based on the ratio of ALM relative to body mass index (BMI) is 
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defined as < 0.789 in men and < 0.512 in women.30,33  The prevalence of sarcopenia in 
adults over 50 varies greatly depending on the definition being used therefore, 
adoption of an operational definition is required for effective prevention and treatment 
strategies to be implemented.2  A universally accepted sarcopenia definition would 
allow effective interventions to be delivered to at risk individuals identified using a 
variety of screening techniques for low ALM and low physical function. 
 
Evolution of Body Composition Evaluation Techniques 
 Since the birth of early methods for assessing body composition, several 
advancements in the techniques for providing accurate regional and total body 
estimates of skeletal muscle mass have become widely available.  Within a very short 
time span in the early 1970s, all three contemporary clinical and reference methods, 
computerized axial tomography (CT), magnetic resonance imaging (MRI), and DXA 
came into existence.34  Early methods (CT and MRI) have more recently developed 
into refined methods that have the ability to quantify regional and total body skeletal 
muscle mass including bioelectrical impedance analysis (BIA) and DXA, all of which 
have advantages and disadvantages.14   
Three dimensional imaging techniques including CT and MRI have the ability 
to quantify all major tissues in the human body.  Computerized axial tomography 
consists of a rotating x-ray tube and detector, which move in a perpendicular plane to 
the subject.  The difference in the attenuation or weakening of the x-rays as they 
penetrate body tissues determines the density of the underlying tissues.  The attenuated 
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x-ray beams can then generate a computer image of the scanned area separating bone, 
adipose tissue, and lean tissue.  An advantage of CT is its ability to construct high-
quality images providing a measure of tissue composition and quality however, the 
degree of radiation exposure and relatively high cost limits its use in research and 
clinical settings.14  Unlike CT scanning, MRI does not use radiation; rather it creates 
images from radio frequency signals emitted by hydrogen nuclei.  The fundamental 
MRI concept is based on interaction between nuclei of abundant hydrogen atoms and 
magnetic fields produced and controlled by the system’s instrumentation.  Application 
of an external magnetic field followed by a pulsed radio frequency across a body part 
causes the hydrogen nuclei to line up and absorb energy.  When the radio wave is 
turned off, the nuclei emit the energy previously absorbed thus, emitting a signal that 
can then be used to create an image.  While CT and MRI are accepted as accurate 
measures of whole body composition, neither are available or affordable methods for 
conducting sarcopenia trials.34,35 
Although CT and MRI provide the most accurate assessment of body 
composition, these reference methods have several limitations including expense, 
equipment availability, and excessive radiation exposure with CT,36 therefore DXA 
has been used more frequently due to its relatively low cost and minimal radiation 
exposure.34,37  DXA uses an x-ray tube to evaluate bone mineral density and soft tissue 
composition.  The attenuation of the x-rays with high and low photon energies is 
measurable and dependent on the thickness, density, and chemical composition of the 
underlying tissue.35  The scan has the ability to evaluate fat, lean soft tissue, and bone 
separately for the extremities, trunk, and other selected body regions.  This segmental 
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analysis can then allow estimation of ALM for assessing skeletal muscle loss with 
aging.34  The availability of DXA, its modest scan cost, low radiation exposure, short 
scan time, and the extensive information provided from each scan has ultimately led to 
this approach being most widely used in sarcopenia research and clinical practice 
today.14  
While DXA is the most widely used method for assessing body composition, 
the use of BIA has grown rapidly in the past two decades as a noninvasive, portable, 
quick, and inexpensive alternative.  Bioelectrical impedance analysis is based on the 
relation between the volume of a conductor and its electrical resistance, therefore 
skeletal muscle is a dominant conductor because it is an electrolyte rich tissue with 
low resistance.10  The devices deliver an alternating current at one or more frequencies 
via electrodes, and impedance to electrical flow is detected.  Electrolyte-rich fluids 
such as body water pose the least impedance to electrical flow, while lipids and bone 
minerals provide the most.  The traditional whole body, single frequency models have 
evolved into segmental multi-frequency models which can measure resistance for each 
body segment at a wide range of frequencies.38  The use of SMF-BIA has become 
more common as segmental analysis of the arm and leg can be empirically calibrated 
to DXA appendicular lean mass however, stable subject conditions are required for 
accurate results.10,14 
 
Comparison between BIA and DXA   
Although several techniques for measuring body composition are available in 
research and clinical practice, DXA is considered to be the gold standard due to its 
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precision for distinguishing fat, bone, and muscle tissue.2,39  As an alternative to CT 
scans and MRI, DXA became available in 1987 as a more practical method with 
limited radiation exposure.34  The ability to isolate body regions during DXA analysis 
allowed many investigators the opportunity to evaluate fat, lean soft tissue, and bone 
mineral content separately for the extremities, trunk, and other selected body regions.  
With the introduction of portable SMF-BIA devices, the same segmental body 
composition analysis could be estimated with no exposure to radiation and at a very 
low cost.2,17,40  While earlier studies supported the validation of DXA using prediction 
equations for the estimation of ALM, future studies would successfully validate the 
use of these prediction equations by BIA.41   
While studies prior to 2003 identified good correlation between BIA and MRI 
using prediction equations, these equations for the estimation of ALM by BIA 
compared to DXA did not yet exist.  Validation of a BIA equation to predict ALM 
compared to DXA was performed by Kyle et al.42 among 444 participants aged 22 to 
94 years.  Using a single frequency bioelectrical impedance device (SF-BIA), a single 
prediction equation taking into account predictor variables including, 
height2/resistance, weight, gender, age, and reactance was used for each participant.  
The results indicated that DXA measured ALM was strongly correlated to the BIA 
derived resistance normalized for height, and that BIA was valid for estimating ALM 
with a standard error between 5% and 7.5% (1.1 kg and 1.5 kg).  While several similar 
prediction equations by BIA have been published and validated against DXA for the 
estimation of skeletal muscle mass (SMM), general BIA prediction equations across 
different ages, ethnic groups, and clinical conditions had not yet been tested.10,42,43  
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The aim of a study performed by Boseaus et al.44 was to validate SF-BIA prediction 
equations developed previously for estimating SMM among 86 male and 66 female 
Australian patients with clinical disorders aged 70 and over compared to DXA.  
Overall, the study demonstrated that SF-BIA, using a prediction equation, gave an 
accurate estimate of DXA derived SMM among participants with a standard error of 
1.68 kg.  With the introduction of validated prediction equations for the estimation of 
total SMM and ALM using BIA, several studies could then investigate the validity of 
several types of single and multi-frequency BIA models among several populations 
compared to DXA.   
Numerous studies have investigated the validity of several bioelectrical 
impedance devices for the measurement of ALM compared to DXA among several 
populations with conflicting results.  In a study by Leahy et al.16 in a healthy adult 
population (n= 403) aged 18 to 29 years, overall agreement between SMF-BIA (Tanita 
MC-180MA) and DXA for the measurement of ALM was observed.  Anderson et al.17 
also reported agreement between SMF-BIA (InBody720) and DXA among the 25 
women aged 18 to 49 years for the estimation of ALM however, among the 25 men, 
an underestimation of ALM of approximately 3.0 kg was observed.17  Another similar 
study identified SMF-BIA (InBody230) as an appropriate alternative to DXA for the 
estimation of fat mass, percent body fat, and total LM but not for the evaluation of 
ALM among a healthy adult population between 18 and 85 years.19  While many 
studies report overall agreement between SMF-BIA and DXA, there appears to be 
consistent observation of a systematic bias with either overestimation or 
underestimation of ALM with some devices.   
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While several studies report overall agreement between several SMF-BIA 
devices among healthy adult populations, others aimed to validate BIA devices among 
older women.  Of the studies that include older women, conflicting results regarding 
the agreement between SMF-BIA and DXA specifically for the measurement of ALM 
have also been observed.15,20  Buckinx et al.15 observed low agreement between SMF-
BIA (InBody S10) and DXA among approximately 25 women in the subcategory of 
participants over the age of 65 (n= 48) using a Bland-Altman plot method.  The study 
reported strong agreement for LM of the upper limbs and low agreement for LM in the 
lower limbs between the two techniques with a tendency for SMF-BIA to overestimate 
ALM by approximately 1.75 kg.15  The participants in the subcategory over the age of 
65 years were more frequently outside the limits of agreement, therefore more 
participants of this age group may have been required for overall agreement to be 
observed.  In a similar study by Kim et al.45 a larger population of community 
dwelling older men (n= 241) and women (n= 331) aged 65 to 87 years were included 
to investigate the validity of SMF-BIA (InBody 720) compared to DXA.  The findings 
of this study compare to previous studies reporting good agreement between the two 
methods for the estimation of ALM, although SMF-BIA had a tendency to 
underestimate ALM among female participants with a bias of 1.59 kg (95% CI 1.49 to 
1.68).45  A study by Kim et al.20 also reported agreement between SMF-BIA (InBody 
720) and DXA among 129 frail community dwelling Japanese women aged 75 to 89 
years.20  Kim et al.20 are the first to assess the validation of SMF-BIA for the measure 
of ALM in a heterogeneous older female participant population.  In order to fill the 
current gap in the literature, future research efforts should investigate the accuracy of 
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other SMF-BIA devices among older Caucasian women for the measurement of ALM 
as a criterion for sarcopenia classification. 
 
Conclusions 
While some studies have reported overall agreement between SMF-BIA and 
DXA for the estimation of ALM among older women, others have reported conflicting 
results.  Additional studies are required to confirm agreement between DXA and 
SMF-BIA under standardized testing conditions that may reduce the systematic bias 
reported by previous investigators.  Despite the evidence in support of SMF-BIA 
accurately estimating ALM, no study to date has investigated the agreement between 
SMF-BIA and DXA among participants with characteristics of sarcopenia and/or 
dynapenia based on current international definitions.  Future studies investigating the 
validation of SMF-BIA compared to DXA for accurate sarcopenia classification based 
on established criteria for low LM based on ALM are also required.  Validation of 
SMF-BIA among populations of older women would provide a more portable and less 
expensive alternative to DXA for clinical and epidemiological screening for 
sarcopenia based on the measurement of ALM in addition to tests of physical function. 
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Appendix B. Phone Screen Assessment 
URI Resistance Exercise Study to Reclaim Lean Muscle and Strength (URI 
RESTORE ME Project) 
Data Sheet for Detailed Subject Telephone Interview 
 
 Brief Explanation of Study 
 Permission to Conduct Interview?      ______Yes   _______No    
 
How did you hear about the study (if not already 
recorded)?___________________________________ 
 
Name:  Dr./Ms./Mrs.________________________________________________ 
Address: ________________________________________________________ 
     ________________________________________________________ 
Phone #:_________________________________________________________ 
E-Mail:___________________________________________________________ 
Best Way and Time to Contact:________________________________________ 
 
 Time Commitment – Available – Include 7-9am or 3-5pm MWF preference 
________________ 
   ____Yes    ____No       Wants to be contacted after ________ (Date)  
Comment:___________________________________________________________
______________ 
 
 Proximity to URI 
Length of commute: ______ miles  or  ______ minutes 
Within reasonable commute_____       Willing to make unreasonable 
commute______ 
Too far to commute______ 
 
 Age 
Age: _____ yrs  Date of Birth:  _____/_____/_____ 
          MM   DD  YY 
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Approximate Height:  ___________ Approximate Weight: ___________  BMI: 
____________ 
 
 Race 
  ___ American Indian or Alaskan Native 
 ___ Asian or Pacific Islander 
   ___ Black, not of Hispanic origin 
   ___ Hispanic 
   ___ White, not of Hispanic origin 
   ___ Other/Unknown 
   
 Highest level of education completed 
 ___ Less than high school 
 ___ High school or GED 
 ___ Some college 
 ___ Two-year college degree (e.g. Associates) 
 ___ Four-year college degree (e.g. B.S., B.A.) 
 ___ Masters degree 
 ___ Doctoral degree 
 ___ Professional degree (e.g. M.D., J.D.) 
 ___ Other (please specify) ________________________________________ 
 
 Have you attained menopause?  Yes ______ No_______ 
If Yes, for how long? _____________________ 
 Smoking  
Always Non-Smoker_______    Non-Smoker for ___________    
Smoker________ 
 
 Physical Activity 
      Participates in regular (>1x/wk for past 3 months) exercise?____Yes _____No  
     If yes, describe in detail (e.g. frequency, intensity, duration, mode) 
____________________________________________________________________
____________________________________________________________________
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____________________________________________________________________
_____________________________________________ 
     Describe other non-structured physical activity (e.g. leisure time, gardening, 
occupational, or other) 
____________________________________________________________________
____________________________________________________________________
______________________________ 
 Cardiovascular (heart, blood, or blood vessel) conditions? 
____No    ____Yes (Record on Medical History/Treatment Form) 
Comments:_____________________________________________________
 ______________________________________________________________ 
 
 Respiratory Conditions? 
____No    ____Yes (Record on Medical History/Treatment Form) 
Comments:_____________________________________________________
 ______________________________________________________________ 
 
 Osteoarthritis/Degenerative Arthritis 
 ___No     ___Yes 
If yes, how long and what was the 
severity________________________________________________________
____________________________________ 
 
 High Blood Pressure 
  No_____  
Yes_____ Controlled (Record High BP and Treatment on Medical 
History/Treatment Form)  
Yes_____ Uncontrolled 
Comments:________________________________________________________
_________________________________________________________________
______________________________ 
 
 Orthopedic conditions (knee, neck, or other back pain) 
___No      ___Yes 
If yes, describe in detail including severity 
______________________________________________________________
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______________________________________________________________
______________________________ 
 
 Diabetes 
 _____No  
_____Yes – Type 2. If type 2, taking insulin now? 
_______________________ 
_____Yes – Type 1 (Insulin Dependent) 
 Comments:____________________________________________________ 
            
_____________________________________________________________  
 
 Any major surgeries as an adult? 
___No      ___Yes 
If yes, what type (e.g. surgeries of the joints, heart surgeries, angioplasty, 
bypass surgery, pacemakers, etc.) and date(s) 
______________________________________________________________
______________________________________________________________
______________________________________________________________
_____________________________________________ 
 
 Other Medical Conditions (especially those that would make exercise difficult 
or unsafe) 
 _____No  
_____Yes (Record on Medical History/Treatment Form)  
Comments:_____________________________________________________
______________________________________________________________
___________________________ 
 
 Medication Info – See last page 
 _____No  
_____Yes (Record on Medical History/Treatment Form)  
Comments:_____________________________________________________
______________________________________________________________
___________________________ 
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 Personal Physician Info 
Name of Physician:  
______________________________________________________ 
Specialty of Physician: 
____________________________________________________ 
 Phone Number:_______________________________________ 
 Fax Number:_________________________________________ 
 Address (if phone and fax unknown):     
           
 
 Summary 
Interviewer Printed Name: ______________________________________ 
        
Interviewer Signature:       ______________________________________ 
 
Questions/Comments:___________________________________ 
          
 
 
 
Reviewer Initials: ______  
 
_____Appears to Qualify  _____Need More Information  
_____Needs Drs. Delmonico, Hatfield, Xu, or Lofgren to review  
_____ Not Qualified 
  
Questions/Comments:         
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Appendix C. Consent Form for Research 
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Appendix D. Medical History 
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Appendix E. Baseline Data Collection Sheet 
 
 
 
 
 
URI RESTORE ME Study Data Sheet 
 
BaselineTesting Day 1 
Participant ID #:    Date: 
 
 
 
 
 
 
 
Measurements Baseline Testing Day 1 Initial 
Resting Heart Rate 1 (bpm)   
Resting Heart Rate 2 (bpm)   
Resting Blood Pressure 1   
Resting Blood Pressure 2   
 
Grip Strength (kilograms)  
Dynamometer Setting: Best Grip Trial: 
Grip R1: Grip R2: Grip L1: Grip L2: 
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Baseline Testing Day 1      
Participant ID#:    Date: 
 
SPPB 
BALANCE SCORING: 
 A. Side-by-side-stand 
o Held for 10 sec ❒ 1 point  
o Not held for 10 sec ❒ 0 points  
o Number of seconds held if less than 10 sec:____sec 
o Not attempted ❒ 0 points 
o If participant did not attempt test or failed, check why: 
o Participant could not walk unassisted ❒ 
o Not attempted, you felt unsafe ❒ 
o Not attempted, participant felt unsafe❒  
o Participant unable to understand instructions ❒ 
o Other (Specify) ❒ 
o Participant refused ❒ 
o If 0 points, end Balance Tests  
 
 B. Semi-Tandem Stand 
o Held for 10 sec ❒ 1 point 
o Not held for 10 sec ❒ 0 points 
o Number of seconds held if less than 10 sec:____sec 
o Not attempted ❒ 0 points 
o If participant did not attempt test or failed, check why: 
o Participant could not walk unassisted ❒ 
o Not attempted, you felt unsafe ❒ 
o Not attempted, participant felt unsafe❒ 
o Participant unable to understand instructions ❒ 
o Other (Specify) ❒ 
o Participant refused ❒ 
o If 0 points, end Balance Tests 
 C. Tandem Stand 
o Held for 10 sec ❒ 2 points 
o Held for 3 to 9.99 sec ❒ 1 point 
o Held for < than 3 sec ❒ 0 points 
o Not attempted ❒ 0 points  
o If participant did not attempt test or failed, check why: 
o Participant could not walk unassisted ❒ 
o Not attempted, you felt unsafe ❒ 
o Not attempted, participant felt unsafe❒  
o Participant unable to understand instructions ❒ 
o Other (Specify) ❒ 
o Participant refused ❒ 
 D. Total Balance Tests score ______(sum points) 
 For 4-Meter Walk:  
o If time is more than 8.70 sec: ❒ 1 point  
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o If time is 6.21 to 8.70 sec: ❒ 2 points  
o If time is 4.82 to 6.20 sec: ❒ 3 points 
o If time is less than 4.82 sec: ❒ 4 points 
CHAIR SCORING: 
 Single Chair Stand Test: 
o Safe to stand without help  YES ❒  NO ❒ 
o Participant stood without using arms  YES ❒  NO ❒If yes go to repeated stand 
o Participant used arms to stand YES ❒ NO ❒If yes end test; score as 0 points 
o Test not completed ❒ End test; score as 0 points 
o If participant did not attempt test or failed, check why: 
o Tried but unable ❒ 
o Participant could not walk unassisted ❒ 
o Not attempted, you felt unsafe ❒ 
o Not attempted, participant felt unsafe❒ 
o Participant unable to understand instructions ❒ 
o Other (Specify) ❒ 
o Participant refused ❒ 
 
 Repeated Chair Stand Test 
o Safe to stand five times Yes❒     No❒  If five stands completed record time 
o Time to complete five stands ___sec 
o If participant did not attempt test or failed, circle why: 
o Tried but unable ❒ 
o Participant could not walk unassisted ❒ 
o Not attempted, you felt unsafe ❒ 
o Not attempted, participant felt unsafe❒ 
o Participant unable to understand instructions❒ 
o Other (Specify) ❒ 
o Participant refused ❒ 
 
 Scoring the Repeated Chair Test 
o Participant unable to complete 5 chair stands or completes stands in >60 sec: ❒  
0 points 
o If chair stand time is 16.70 sec or more: ❒  1 points 
o If chair stand time is 13.70 to 16.69 sec: ❒  2 points 
o If chair stand time is 11.20 to 13.69 sec: ❒  3 points 
o If chair stand time is 11.19 sec or less: ❒  4 points 
 
 Scoring for Complete Short Physical Performance Battery 
 Total Balance Test score _____ points 
 Gait Speed Test score _____ points 
 Chair Stand Test score _____ points 
 Total Score _____ points (sum of points above) 
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Test    Result Date Completed Initial 
400m walk 
(sec) 
   
SPPB points scored   
Single Leg 
Stand, 10 sec 
   
Sit and Reach 
(+/- cm) 
   
Timed Up 
and Go 1 
(sec) 
   
Timed Up 
and Go 2 
(sec) 
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Baseline Testing 
Participant ID #:    Date:    
   
Notes: 
 
 
Measurements Date Initial 
Resting Heart Rate 1 (bpm)   
Resting Heart Rate 2 (bpm)   
Resting Blood Pressure 1   
Resting Blood Pressure 2   
Blood Draw 1   
 
Anthropometrics Measurement 
1 
Measurement 
2 
Average Initial 
Height (inches)     
 Weight (lbs)     
Waist 
Circumference 
(inches) 
    
Hip 
Circumference 
(inches) 
    
BMI (kg/m2)  Waist to Hip 
Ratio 
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Baseline Testing  
Participant ID#:    Date:     
 
 Results collected Date   Initial 
DEXA    
 
Measurements Baseline Testing Day 1 Initial 
Resting Heart Rate 1 
(bpm) 
  
Resting Heart Rate 2 
(bpm) 
  
Resting Blood Pressure 
1 
  
Resting Blood Pressure 
2 
  
Blood Draw 2 
 
  
 
In-Body: BIA Date:        
Voided Bladder 
          Yes   No 
Height: Weight: BMI:  
R Arm LM: L Arm LM: R Leg LM: L Leg LM: 
 Total ALM: 
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Appendix F. Yale Physical Activity Survey 
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Appendix G. Dietary Screening Tool 
 
DIRECTIONS: Please check one response to each question that best describes how 
you eat.  
 
How often do you usually eat fruit as a snack?  
____ Never  
____ Less than once a week  
____ 1 or 2 times a week  
____ 3 or more times a week  
 
How often do you usually eat whole grain breads?  
____ Never or less than once a week  
____ 1 or 2 times a week  
____ 3 or more times a week  
 
How often do you usually eat whole grain cereals?  
____ Never or less than once a week  
____ 1 or 2 times a week  
____ 3 or more times a week  
 
How often do you usually eat candy or chocolate?  
____ Never  
____ Less than once a week  
____ 1 or 2 times a week  
____ 3 or more times a week  
 
How often do you eat crackers, pretzels, chips, or popcorn?  
____ Never  
____ Less than once a week  
____ 1 or 2 times a week  
____ 3 or more times a week  
 
How often do you eat cakes or pies?  
____ Never  
____ Less than once a week  
____ 1 or 2 times a week  
____ 3 or more times a week 
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How often do you eat cookies?  
____ Never  
____ Less than once a week  
____ 1 or 2 times a week  
____ 3 or more times a week  
 
How often do you eat ice cream?  
____ Never  
____ Less than once a week  
____ 1 or 2 times a week  
____ 3 or more times a week  
 
How often do you eat cold cuts, hot dogs, lunchmeats or deli meats?  
____ Never or less than once a week  
____ 1 or 2 times a week  
____ 3 or more times a week  
 
How often do you eat bacon or sausage?  
____ Never or less than once a week  
____ 1 or 2 times a week  
____ 3 or more times a week  
 
How often do you eat carrots, sweet potatoes, broccoli, or spinach?  
____ Never  
____ Less than once a week  
____ 1 or 2 times a week  
____ 3 or more times a week  
 
How often do you eat fruit (not including juice)? Please include fresh, canned or 
frozen fruit.  
____ Never or Less than once a week  
____ 1 or 2 times a week  
____ 3 to 5 times a week  
____ Every day or almost every day  
 
How often do you eat hot or cold breakfast cereal?  
____ Never  
____ Less than once a week  
____ 1 or 2 times a week  
____ 3 to 5 times a week  
____ Every day or almost every day  
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How often do you drink some kind of juice at breakfast?  
____ Never or Less than once a week  
____ 1 or 2 times a week  
____ 3 to 5 times a week  
____ Every day or almost every day  
 
How often do you eat chicken or turkey?  
____ Never or less than once a week  
____ 1 or 2 times a week  
____ More than 3 times a week  
 
How often do you drink a glass of milk?  
____ Never or Less than once a week  
____ 1 or 2 times a week  
____ 3 to 5 times a week  
____ Every day or almost every day  
____ More than once every day  
 
Do you usually add butter or margarine to foods like bread, rolls, or biscuits?  
____ Yes  
____ No  
 
Do you usually add fat (butter, margarine or oil) to potatoes and other 
vegetables?  
____ Yes  
____ No  
 
Do you use gravy (when available) at meals?  
____ Yes  
____ No  
 
Do you usually add sugar or honey to sweeten your coffee or tea?  
____ Yes  
____ No  
 
Do you usually drink wine, beer or other alcoholic beverages?  
____ Yes  
____ No 
76 
 
How often do you eat fish or seafood that IS NOT fried?  
____ Never  
____ Less than once a week  
____ Once a week  
____ More than once a week  
 
How many servings of milk, cheese, or yogurt do you usually have each DAY?  
____ None  
____ One  
____ Two or more  
 
How many different vegetable servings do you usually have at your main meal of 
the day?  
____ None  
____ One  
____ Two  
____ Three or more  
 
Which of the following best describes your nutritional supplement use?  
____ I don’t use supplements  
____ I use supplements other than vitamins and mineral  
____ I use a multivitamin/mineral preparation (e.g. Centrum) 
 
 
 
 
 
 
